CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. - Wikidata - awgldk - TriplyDB

CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients.

CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients.

http://www.wikidata.org/entity/Q34154427

about

Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+) T cell responses for tumor immunity Dendritic cells loaded with killed breast cancer cells induce differentiation of tumor-specific cytotoxic T lymphocytes Oral vaccination with attenuated Salmonella enterica strains encoding T-cell epitopes from tumor antigen NY-ESO-1 induces specific cytotoxic T-lymphocyte responses.LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein.The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes.Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.Recent progress in tumour vaccine development.Antigen-specific immunotherapy and cancer vaccines.Increased NY-ESO-1 expression and reduced infiltrating CD3+ T cells in cutaneous melanoma.Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients.Enhanced Recognition of HIV-1 Cryptic Epitopes Restricted by HLA Class I Alleles Associated With a Favorable Clinical Outcome.Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1.The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens NY-ESO-1 immunotherapy for multiple myeloma.Identification of T-cell epitopes for cancer immunotherapy.Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1.Melanoma vaccines: developments over the past 10 years.Colorectal cancer vaccines in clinical trials.Towards in silico design of epitope-based vaccines.Evolving role of tumor antigens for future melanoma therapies.New York esophageal squamous cell carcinoma-1 and cancer immunotherapy.Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide.In silico and cell-based analyses reveal strong divergence between prediction and observation of T-cell-recognized tumor antigen T-cell epitopes.Induction of CAMEL/NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/35 fiber.Cross-presentation of a CMV pp65 epitope by human dendritic cells using bee venom PLA2 as a membrane-binding vector.NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer.Functional and structural characteristics of NY-ESO-1-related HLA A2-restricted epitopes and the design of a novel immunogenic analogue.Neoantigen prediction and the need for validation.DNA fusion vaccine designs to induce tumor-lytic CD8+ T-cell attack via the immunodominant cysteine-containing epitope of NY-ESO 1.Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis.

P2860

Q24610550-9952ED9E-F228-45C2-9021-013A8C5F03EC Q24806024-E1B190D8-D5BC-4D9B-AF3B-00FC6A8B76CE Q33909195-6EFC441E-FF64-4A4D-9316-50269E448746 Q34111719-40DB205C-CCF6-4C4E-B137-DDCEEF28CA6A Q34111757-FE165B43-E25D-40F5-BDA4-53818A1309BC Q34309388-0444F41A-1A28-4DCA-B4EA-B0C5661629B8 Q34627677-DFBCCE86-927B-4C96-8488-5813E1AC9623 Q34795354-5E9F3628-B320-4BB2-82E7-D965D0158E45 Q35039508-4C90C723-25EA-4182-A729-798743953376 Q35144001-3113ECCC-9CD2-4909-A406-10D4D3063D7E Q35199473-49565059-B457-47AC-B6F3-BECDDA77B8CA Q35543740-DEF1EFF1-DAEE-4A47-843A-4C7B0CCEBF12 Q35921697-F410D3BA-BD9B-4C4E-A797-A171B86DB0E4 Q35939427-320E8413-AB05-4548-8B89-6C2C54506731 Q36015624-46328A8A-1F6F-419A-9968-6A98628E0BDA Q36471827-B23AE958-5F9F-4F21-B0D0-FD9010601798 Q36611909-B32E91CD-5BC0-4E2F-A87E-945FDF98B1E2 Q36637651-4A8E4CA7-B855-4C06-82A6-CB55AD5D417E Q36870592-80A6F87B-CEEC-4E39-8AB2-04C5C66D2073 Q37762274-58D8A9A0-FE23-43E6-83C0-3B5382C718D5 Q37892595-C67B56B3-52F7-48CB-ACA5-B6336975BAD6 Q37892600-FAFBE6F2-61C6-4F38-91DC-8D3BA2332352 Q38088325-1BD46EAA-5C5C-4C65-BAC4-7F99AF310DB0 Q38232855-731AF27D-A638-4F1C-AB80-6F01980C1759 Q38445350-8A2E65D5-15E8-4785-B970-C7AEAD1EFA9C Q38693404-19C69D5C-D28B-4094-A827-373EC874E6BA Q39325954-4A3DF072-A61B-43DB-A9C2-EE97AC9E3A4D Q40188864-09E6C07D-6CA8-46B8-844C-CE5503760077 Q40598793-96565A58-9BFE-46B0-BC59-FC03D62F8891 Q41912576-B9323636-FD05-4DA3-8457-A7A9FEAA94DB Q44264589-414F1CDB-6B5E-4056-B51A-4FC4BB520C31 Q44788642-D447CE0E-28DD-42EC-A18A-2EE1492A2DE9 Q46969749-E2CBB379-E4AE-4F0D-B5F8-8149AA3E5F2B Q51825111-BB004EDE-0D19-4C41-BBEF-1C3D7AC53E86 Q55136811-04B58758-12DC-4CA6-B022-7DBF216FEA01

P2860

CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients.

http://www.wikidata.org/entity/Q34154427

description

2002 nî lūn-bûn

@nan

2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

CD8(+) T cell responses agains ...... munization of cancer patients.

@ast

CD8(+) T cell responses agains ...... munization of cancer patients.

@en

type

label

CD8(+) T cell responses agains ...... munization of cancer patients.

@ast

CD8(+) T cell responses agains ...... munization of cancer patients.

@en

prefLabel

CD8(+) T cell responses agains ...... munization of cancer patients.

@ast

CD8(+) T cell responses agains ...... munization of cancer patients.

@en

P1433

Q34154427-7AD2C908-DB4F-4E42-848B-2F5E23DF8DBB

P1476

Q34154427-FE789BA6-EB3F-4863-A8A2-08699BC9E02D

P2093

Q34154427-1D37863A-4CD9-4A77-B138-3F5A60A6AE5C

Q34154427-1D74C2EA-B33E-45A6-952E-664D3421849F

Q34154427-3126170E-6D47-4F3A-A13B-F65DF4929C5C

Q34154427-3989D3DC-7746-412C-BB07-5A9C7D0605CD

Q34154427-5F26E06F-D184-433F-BB01-8491B0CE6608

Q34154427-8D2EDB9D-9990-42C4-80DA-A474DADC4517

Q34154427-90DDB8CE-46CD-4644-8DFB-5EC6DBF87B33

Q34154427-9C9F755F-37AA-4C26-BDC9-EBC3B233614C

Q34154427-A36A6593-5180-4798-A0D5-A73CBFDD61F0

Q34154427-B01A1846-2A9D-44C1-9915-CE65B6383657

P2860

Q34154427-03E8286F-6FCF-43BA-9F95-A69091487A8F

Q34154427-060385E8-8212-4794-A6C1-2446691BB152

Q34154427-0895FEEF-7C62-4A95-A3E2-1BE153213A9C

Q34154427-1043101D-024E-4C4A-BF73-1A4A5618311E

Q34154427-191CEF35-BD1C-4148-A329-A6754106B56E

Q34154427-22E7E18A-198F-4121-9765-74E3E4AC32EF

Q34154427-2E55EE60-E842-470C-A240-FE714BB80DE5

Q34154427-3089AF3C-3056-4977-9403-F31A9FE786E9

Q34154427-3D1AEDB3-35C8-46D3-9C5F-3021F53B74FB

Q34154427-3D63391B-44C3-40F0-A382-C429CAFF475E

P304

Q34154427-B1DBB112-B2DE-47CE-B78C-C55CBBDB0C4F

P31

Q34154427-449D3B7C-6935-440E-A4CA-AAFB5295C696

P356

Q34154427-33559813-F30E-4F95-AF0C-7A1D01382D42

P407

Q34154427-9C1C72D7-6D1C-42A4-BE6D-C374BDD4D485

P433

Q34154427-B2602971-ECB6-459F-AE00-F4A3B1D16F06

P478

Q34154427-4BE7579E-EBC2-4A42-AA06-7EA551A4489B

P577

Q34154427-51FB672C-A30E-457B-A16E-1EB0CAF2DEB6

P5875

Q34154427-E2535774-EFCC-4F49-9EF1-9BDEECEDC303

P698

Q34154427-A6C18CBF-AE06-4361-840F-6CAE16B871CC

P921

Q34154427-D8846E81-CC5C-4F92-AE01-06FD73A38D69

P932

Q34154427-4668D883-F0CB-419F-B518-E6B116B213AF

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

CD8(+) T cell responses agains ...... munization of cancer patients.

@en

P2093

Alexander Knuth

http://www.w3.org/2001/XMLSchema#string

Djordje Atanackovic

http://www.w3.org/2001/XMLSchema#string

Elke Jäger

http://www.w3.org/2001/XMLSchema#string

Gerd Ritter

http://www.w3.org/2001/XMLSchema#string

Jonathan Cebon

http://www.w3.org/2001/XMLSchema#string

Lloyd J Old

http://www.w3.org/2001/XMLSchema#string

Mitsutoshi Matsuo

http://www.w3.org/2001/XMLSchema#string

Nasser K Altorki

http://www.w3.org/2001/XMLSchema#string

Qiyuan Chen

http://www.w3.org/2001/XMLSchema#string

Sacha Gnjatic

http://www.w3.org/2001/XMLSchema#string

P2860

A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma

Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations.

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

Phenotypic analysis of antigen-specific T lymphocytes

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

Exploitation of the B cell repertoire for the identification of human tumor antigens.

Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library.

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.

Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells.

Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains.

P304

11813-11818

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.142417699

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P577

2002-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11200551

http://www.w3.org/2001/XMLSchema#string

P698

12186971

http://www.w3.org/2001/XMLSchema#string

P921

P932

129351

http://www.w3.org/2001/XMLSchema#string